Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mesenchymal stem cell-derived exosomes for decompensated liver cirrhosis
IRCT20200809048342N3Phase 2Completed
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Apr 2023
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of mesenchymal stem cell exosomes in Cirrhosis, sponsored by Shahid Beheshti University of Medical Sciences. Primary endpoint: Liver function including Child score and MELD score at 16 weeks. Started Apr 2023; status: completed.
02
Drugs
mesenchymal stem cell exosomes
03
Conditions
Cirrhosis
Beyond the preview
Go deeper on IRCT20200809048342N3.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200809048342N3.